Patents by Inventor James J. S. Treanor

James J. S. Treanor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS
    Publication number: 20160304596
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 20, 2016
    Applicants: AMGEN INC., E.R. SQUIBB & SONS, L.L.C.
    Inventors: Kenneth D. WILD, Jr., James J.S. TREANOR, Haichun HUANG, Heather INOUE, Tie J. ZHANG, Frank MARTIN
  • Human Anti-NGF Neutralizing Antibodies As Selective NGF Pathway Inhibitors
    Publication number: 20160237147
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: January 19, 2016
    Publication date: August 18, 2016
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Methods of treating conditions caused by increased expression of nerve growth factor (NGF) or increased sensitivity to NGF using anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
    Patent number: 9260514
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of these antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: February 16, 2016
    Assignees: Amgen Inc., E. R. Squibb & Sons, L.L.C.
    Inventors: Kenneth D. Wild, Jr., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
    Patent number: 8198410
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: June 12, 2012
    Assignee: Amgen Inc.
    Inventors: Kenneth D. Wild, Jr., James J. S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
    Patent number: 8106167
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of these antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: January 31, 2012
    Assignee: Amgen Inc.
    Inventors: Kenneth D. Wild, Jr., James J. S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
    Publication number: 20110091476
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: September 13, 2010
    Publication date: April 21, 2011
    Applicants: AMGEN INC., MEDAREX, INC.
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
    Publication number: 20110040076
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: August 18, 2010
    Publication date: February 17, 2011
    Applicants: AMGEN INC., MEDAREX, INC.
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
    Patent number: 7795413
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: September 14, 2010
    Assignee: Amgen, Inc.
    Inventors: Kenneth D. Wild, Jr., James J. S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
    Publication number: 20100034818
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: October 9, 2009
    Publication date: February 11, 2010
    Applicants: AMGEN, INC., MEDAREX, INC.
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT
    Publication number: 20090312433
    Abstract: The present invention relates to a method of reducing a VR1-antagonist-induced increase in body temperature in a mammal in need thereof, comprising the step of administering an antipyretic agent to the mammal and the like.
    Type: Application
    Filed: August 28, 2009
    Publication date: December 17, 2009
    Inventors: Anthony W. Bannon, Klaus D. Beck, James J.S. Treanor
  • Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
    Patent number: 7601818
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: October 13, 2009
    Assignees: Amgen, Inc., Medarex, Inc.
    Inventors: Kenneth D. Wild, Jr., James J. S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS
    Publication number: 20090155274
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: November 25, 2008
    Publication date: June 18, 2009
    Applicants: AMGEN INC., MEDAREX, INC.
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin